Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.23 | N/A | +15.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.23 | N/A | +15.60% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They are prioritizing cost management but did not provide future guidance.
Management highlighted ongoing challenges in the market.
They emphasized a focus on cost management and efficiency.
There was no specific guidance provided for future quarters.
Amgen's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by over 5% in reaction, likely due to the lack of revenue details and no forward guidance. Investors may be concerned about the company's future performance amidst market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS INSTRS INC
Oct 20, 2008